FutureTech II hires D. Boral as financial advisor for Longevity de-SPAC, corrects $1.475M note contingency

FutureTech II Acquisition Corp.

Engaged D. Boral Capital as sole financial advisor for de-SPAC business combination with Longevity Biomedical (announced Feb 2025).
D. Boral receives a 36-month irrevocable right of first refusal on future equity/debt offerings and M&A transactions after the closing.
Corrected $1.475M promissory note to D. Boral for deferred underwriting commission now explicitly contingent on closing.
Original note mistakenly omitted the closing contingency; corrected note resolves the error.
Agreements signed March 4, 2026; engagement letter has 12-month initial term with termination provisions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

FutureTech II Acquisition Corp. amended Corrected D. Boral Note with D. Boral Capital, LLC valued at Corrected promissory note principal amount $1,475,000, contingency added (effective 2026-03-04).

Action: amendment
Agreement: notes offering
Counterparty: D. Boral Capital, LLC
Value: Corrected promissory note principal amount $1,475,000, contingency added
Effective: 2026-03-04

Exact text from the filing

On March 4, 2026, the Company, Longevity and D. Boral corrected the mistake by executing a corrected promissory Note in the principal amount of $1,475,000 (the “Corrected D. Boral Note”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

FutureTech II Acquisition Corp. entered into Engagement Letter with D. Boral Capital, LLC valued at D. Boral will serve as sole and exclusive financial advisor (effective 2026-03-04).

Action: entry
Agreement: underwriting
Counterparty: D. Boral Capital, LLC
Value: D. Boral will serve as sole and exclusive financial advisor
Effective: 2026-03-04

Exact text from the filing

On March 4, 2026, FutureTech II Acquisition Corp. (“FutureTech” or the “Company”) entered into an engagement letter (the “Engagement Letter”) with D. Boral Capital, LLC (“D. Boral”) pursuant to which both parties agreed that D. Boral will serve as the Company’s sole and exclusive financial advisor in connection with a De-SPAC business combination between Longevity Biomedical, Inc. (“Longevity”) and the Company (the “Business Combination”) announced in the Form S-4 registration statement dated February 14, 2025.

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001493152-26-009455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.